Secondary analysis of 592 patients with newly diagnosed glioblastoma from the AVAglio trial: right prefrontal location was favourable (median HR 0.57) and left eloquent areas unfavourable (HR 1.69); bevacizumab effects by location did not survive correction.
Secondary analysisn = 592
Sanvito et al. Framework for Statistical Parametric Mapping of the Interactions between Glioblastoma Location, Treatment, Prognostic Variables, and Survival Using a Phase III Trial